Apollomics is an innovative biotechnology company focusing on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer.
Recent News
- Apollomics Regains Full Compliance with Nasdaq Listing Requirements
- Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
- Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress